GlassScriptPhysician profile
Daniel M Peraza
NPI 1073635355
$6,536.64
in general payments reported to CMS, 2019-2025
9 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $750 · 2021: $520 · 2022: $2,422 · 2023: $883 · 2024: $839 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Food and Beverage: $410 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Food and Beverage | $409.79 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,135.00 | 2019-2024 | |
| Allergan, INC. | $1,800.00 | 2022 | |
| Janssen Biotech, INC. | $341.94 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $169.99 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $21.51 | 2019 | |
| Leo Pharma INC. | $20.18 | 2021 | |
| Mimedx Group, INC. | $19.59 | 2025 | |
| Pfizer INC. | $15.27 | 2024 | |
| Dusa Pharmaceuticals, INC. | $13.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Peraza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.